Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

40.0%

2 terminated/withdrawn out of 5 trials

Success Rate

50.0%

-36.6% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
4(100.0%)
4Total
Phase 1(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT06716788Not Yet Recruiting

68Ga-HSA PET/CT Imaging for Protein-losing Enteropathy

Role: collaborator

NCT04272944Phase 1Completed

A Study of MSB2311 in Advanced Solid Tumors

Role: lead

NCT03463473Phase 1Completed

A Phase I Study of MSB2311 in Advanced Solid Tumors

Role: lead

NCT04958434Phase 1Terminated

Study of TST005 in Patients With Locally Advanced or Metastatic Solid Tumors

Role: lead

NCT04381325Phase 1Terminated

A Study of MSB0254 Injection in Advanced Solid Tumors

Role: lead

All 5 trials loaded